SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Thrasos Therapeutics Issued U.S. Patent for First-in-Class Compounds That Selectively Target Key Receptors of the Bone Morphogenetic Protein Pathway